daVinci Digital Therapeutics

DaVinci Digital Therapeutics is a digital health company specializing in the development of evidence-based digital therapeutics (DTx) for chronic conditions. The company's software-as-a-medical-device (SaMD) solutions are designed to deliver therapeutic interventions that complement traditional pharmacological treatments, focusing on behavioral changes to improve patient outcomes. Their portfolio primarily targets metabolic and sleep disorders, including obesity and insomnia. The company utilizes a proprietary platform to create digital solutions that provide real-time monitoring and personalized support for patients. In February 2023, the company was acquired by Chiesi Farmaceutici, a global pharmaceutical group, to serve as a center of excellence for digital health innovation. This acquisition allows for the integration of digital tools with Chiesi's existing respiratory and rare disease treatments.